• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Cancer Cachexia - Pipeline Review, H2 2012 Product Image

Cancer Cachexia - Pipeline Review, H2 2012

  • Published: November 2012
  • 85 pages
  • Global Markets Direct

Cancer Cachexia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Cancer Cachexia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cancer Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Cachexia. Cancer Cachexia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cancer Cachexia.
- A review of the Cancer Cachexia products under development by companies and universities/research institutes based READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Cancer Cachexia Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Cancer Cachexia 9
Cancer Cachexia Therapeutics under Development by Companies 11
Cancer Cachexia Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Cancer Cachexia Therapeutics – Products under Development by Companies 18
Cancer Cachexia Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Cancer Cachexia Therapeutics Development 20
Eli Lilly and Company 20
AEterna Zentaris Inc. 21
Santhera Pharmaceuticals Holding AG 22
Helsinn Healthcare S.A. 23
Alder Biopharmaceuticals Inc. 24
Tranzyme Pharma, Inc. 25
Elixir Pharmaceuticals, Inc. 26
Vicus Therapeutics, LLC 27
OHR Pharmaceutical Inc. 28
XBiotech USA, Inc. 29
Acacia Pharma Ltd. 30
Cancer Cachexia – Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
AEZS-130 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ulimorelin hydrochloride - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
clazakizumab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
EX-1314 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
anamorelin hydrochloride - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
anamorelin hydrochloride - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Megestrol + Formoterol - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
propranolol + etodolac - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
OHR/AVR-118 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
etodolac + propranolol + sorafenib - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
MT-102 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
LY-2495655 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Drug For Cancer Cachexia - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
mirtazapine + megestrol acetate - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Ghrelin Receptor Agonists - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Drug Targeting PIFR - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Xilonix - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
SNT-207707 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
SNT-209858 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Drugs For Cancer Cachexia - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Cancer Cachexia Therapeutics – Drug Profile Updates 65
Cancer Cachexia Therapeutics – Discontinued Products 74
Cancer Cachexia Therapeutics - Dormant Products 75
Cancer Cachexia – Product Development Milestones 76
Featured News & Press Releases 76
Oct 08, 2012: GTx To Present Scientific Poster Presentations On Enobosarm At International Society Of Geriatric Oncology 76
Oct 03, 2012: XBiotech Receives Fast Track Designation From FDA For Anti-Cachexia Drug Xilonix 76
Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130 77
Jun 25, 2012: GTx Announces Presentation On Enobosarm’s Improvement In Physical Function In Cancer Patients With Both Low And Normal Testosterone Levels 78
Mar 30, 2012: XBiotech Announces FDA Approval To Launch Phase II Study Of Xilonix As Treatment For Cachexia In Subjects With Metastatic Cancers 79
Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130 79
Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference 80
Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study 81
Nov 28, 2011: FDA Grants IND To Investigator At Baylor College Of Medicine For Phase IIa Trial With AEZS-130 In Cancer Cachexia 81
May 17, 2011: Ohr Pharmaceutical Receives Canadian Composition-of-Matter Patent For OHR/AVR118 83
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 84
Contact Us 85
Disclaimer 85

List of Tables
Number of Products Under Development for Cancer Cachexia, H2 2012 9
Products under Development for Cancer Cachexia – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Development by Companies, H2 2012 (Contd..1) 13
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Eli Lilly and Company, H2 2012 20
AEterna Zentaris Inc., H2 2012 21
Santhera Pharmaceuticals Holding AG, H2 2012 22
Helsinn Healthcare S.A., H2 2012 23
Alder Biopharmaceuticals Inc., H2 2012 24
Tranzyme Pharma, Inc., H2 2012 25
Elixir Pharmaceuticals, Inc., H2 2012 26
Vicus Therapeutics, LLC, H2 2012 27
OHR Pharmaceutical Inc., H2 2012 28
XBiotech USA, Inc., H2 2012 29
Acacia Pharma Ltd., H2 2012 30
Assessment by Monotherapy Products, H2 2012 31
Assessment by Combination Products, H2 2012 32
Assessment by Stage and Route of Administration, H2 2012 34
Assessment by Stage and Molecule Type, H2 2012 36
Cancer Cachexia Therapeutics – Drug Profile Updates 65
Cancer Cachexia Therapeutics – Discontinued Products 74
Cancer Cachexia Therapeutics – Dormant Products 75

List of Figures
Number of Products under Development for Cancer Cachexia, H2 2012 9
Products under Development for Cancer Cachexia – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Discovery and Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 31
Assessment by Combination Products, H2 2012 32
Assessment by Route of Administration, H2 2012 33
Assessment by Stage and Route of Administration, H2 2012 34
Assessment by Molecule Type, H2 2012 35
Assessment by Stage and Molecule Type, H2 2012 36

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos